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Therapeutic effects of hybrid liposomes (HL) composed of L-a-dimyristoylphosphatidylcholine (DMPC)
and polyoxyethylene(25) dodecyl ether (C12(EO)25) on the metastasis of human colon carcinoma
(HCT116) cells were examined in vivo. Remarkably high therapeutic effects were obtained in the xeno-
graft mouse models of colorectal cancer (CRC) liver metastases after treatment with HL-25 on the basis of
relative liver weight and histological analysis of the liver tissue sections of mouse models with HE
staining, and TUNEL staining for detection of apoptotic cells. The survival effects of HL-25 were obtained
using xenograft mouse models of CRC liver metastases. Furthermore, with regard to pharmacokinetics,
the accumulation of ﬂuorescent labeled HL-25 was observed in the liver tissue of xenograft mouse
models of CRC liver metastases for 24 h after the intravenous injection of ﬂuorescent labeled HL-25.
Therapeutic effects of HL without any drugs on the liver metastasis of human CRC were revealed for
the ﬁrst time in vivo.
 2012 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
It is well known that colorectal cancer (CRC) has remarkably high
metastaticity, leading to cancer-related death with the majority of
deaths attributable to distant metastases, and the liver is the most
commonsiteofhematogenousmetastasis inCRC.Approximately20%
of patients present with synchronous liver metastasis at the time of
diagnosis, and the other 30% of patientswill develop livermetastasis
after resection of the primary CRC. Accordingly, elucidation of the
mechanism in liver metastasis is critical for improvement of the
survival rate in CRC. Liver resection combined with chemotherapy is
the standard of treatment for patients with CRC liver metastasis [1].
However, with enlarged and advanced cancer into the deeper
regions, it is difﬁcult to cure caseswith surgical treatment. Therefore,
an effective chemotherapy for advanced liver metastasis of colon
carcinoma has not been established [2,3].
Hybrid liposomes, which are speciﬁc nanoparticles, ﬁrst devel-
oped by Ueoka et al. [4,5], can be prepared by simply sonicatingdecyl ether; CRC, colorectal
HL-25, hybrid liposomes
lmitoyl-2-[12-[(7-nitro-2-1,3-
phosphocholine; RES, retic-
eotidyl transferase-mediated
: þ81 96 326 0522.
.
der CC BY-NC-ND license.a mixture of vesicular and micellar molecules in buffer solutions.
Inhibitory effects of HL including ﬂavonoids [6], antitumor drugs [7],
sugar surfactants [8e10], orpolyunsaturated fattyacids [11,12]on the
growth of tumor cells in vitro and in vivo have been obtained. On the
other hand, remarkably high inhibitory effects of HL on the growth of
tumor cells in vitro [13e16] and in vivo [16e19] have been obtained
without drugs. Furthermore, successful clinical chemotherapy with
drug-freeHL to patientswith lymphoma has been reported [20e22].
In addition, it has been demonstrated that HL could induce apoptotic
cell death in tumor cells [13e22]. With respect to colon cancer cell
lines, HL induced apoptosis in human colon adenocarcinoma WiDr
[23] and HCT116 cells [24]. However, therapeutic effects and phar-
macokinetics of HL on the mouse models of human CRC liver
metastases in vivo have not yet been elucidated.
In this study, we investigated the therapeutic effects of HL-25
composed of L-a-dimyristoylphosphatidylcholine (DMPC) and
polyoxyethylene(25) dodecyl ether (C12(EO)25) using xenograft
mouse models of CRC liver metastases after the inoculation of
human colon carcinoma (HCT116) in vivo.
2. Results and discussions
2.1. Physical properties of HL-25
We examined the morphology of HL-25 composed of 95 mol%
DMPC and 5 mol% C12(EO)25 on the basis of dynamic light scat-
tering measurements. As shown in Fig. 1B, the hydrodynamic
Fig. 1. (A) Schematic representation of HL-25. (B) Time courses of dhy change for hybrid
liposomes composed of 95 mol% DMPC and 5 mol% C12(EO)25 in 5% glucose solution at
25 C. [DMPC] ¼ 2.0  102 M, [C12(EO)25] ¼ 1.05  103 M.
Fig. 2. Survival curves of mouse models of CRC liver metastases after the treatment
with HL-25.
Fig. 3. (A) Liver of mouse models of CRC liver metastases treated with HL-25. Scale bar,
10 mm. (B) Relative liver weight of mouse models of CRC liver metastases treated with
HL-25.
H. Ichihara et al. / European Journal of Medicinal Chemistry 57 (2012) 143e148144diameter (dhy) of HL-25 was under 100 nm, which was preserved
for a period that remained stable for more than one month. On the
other hand, DMPC liposomes were unstable and precipitated after
14 days. HL were kept at room temperature (25 C) due to the
convenience of stock for a long term period for clinical application.
It is suggested that the diameter of HL gradually decreased, since
the membrane ﬂuidity of HL that was kept at room temperature
near phase transition temperature (21 C) [26] gradually stabilized
after a preparation at 45 C. Furthermore, the diameter of HL
spontaneously recovered to 100 nm from 50 nm by increasing
temperature from room temperature to 37 C. It is worthy to note
that HL-25 having under the 100 nm in diameter could avoid
the reticular endothelial system (RES) [27] and should be appro-
priate for the intravenous administration in vivo and clinical
applications.
2.2. Prolonged survival effects of HL for xenograft mouse models of
CRC liver metastases in vivo
We examined the therapeutic effects of HL-25 using xenograft
mouse models of CRC liver metastases after the intravenous
treatment with HL-25. HL were intravenously administered via
a caudal vein once each day for 14 days after the inoculation of
HCT116 cells. After dosing period, survival of mice were followed.
The results are shown in Fig. 2. The median survival time for the
group treated with HL-25 (38  6) was longer than that for the
control group (30 0). On the other hand, themedian survival time
for the group treated with DMPC was 32  5 and the statistically
signiﬁcant difference between control and DMPC alone was not
obtained. It is noteworthy that a prolonged survival rate (130%,
p < 0.05) was obtained in the group treated with HL-25. Theseresults indicate that HL-25 could strongly inhibit the growth of
HCT-116 cells in vivo.
2.3. Therapeutic effects of HL-25 on CRC liver metastases in vivo
We examined the inhibitory effects of HL-25 on the growth of
tumors in xenograft mouse models of CRC liver metastases after
intravenous treatment. HL-25 was administered into the caudal
vein of mice once each for 14 days after the HCT116 cells were
inoculated to mice. Liver was removed from anaesthetized mice
immediately after the treatment with HL-25. First, we examined
the therapeutic effects of HL-25 on the liver metastasis mouse
models in an autopsy. The results are shown in Fig. 3A. The livers of
Fig. 5. TUNEL staining of liver tissue of mouse models of CRC liver metastases treated
with HL-25. Arrow indicates apoptotic cells. Scale bar, 100 mm.
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normal group, although the enlargement and the tumor-nodes by
metastasis of HCT116 cells in the livers of the untreated control
group and those treated with DMPC were conﬁrmed. Next, we
examined the relative liver weight of mouse models of CRC liver
metastases treated with HL. The results are shown in Fig. 3B. It is
worthy to note that the relative liver weight of the group treated
with HL-25 was close to that of the normal group, although that of
the untreated control group obviously increased. There was
a signiﬁcant difference (p < 0.05) in the relative liver weight
between the untreated control group and the HL-25 treated group.
These results indicate that HL-25 could be effective for the liver
metastasis mouse models in vivo.
2.4. Histological bioanalysis
We histologically evaluated the therapeutic effects of HL-25
using the liver tissue for the mouse models of CRC liver metas-
tases in vivo. HL-25 was administered into the caudal vein of mice
once each for 14 days after the HCT116 cells were inoculated to
mice. Liver was removed from anaesthetized mice immediately
after the treatment with HL-25. We examined hematoxylin and
eosin (HE) staining to evaluate the therapeutic effects of HL-25. As
shown in Fig. 4, it was conﬁrmed that the large metastatic nodules
were obviously observed in the livers of the untreated control
group and the group treated with DMPC, indicating a malignant
transformation by metastasis of carcinoma cells in the liver. On
the other hand, no abnormal ﬁndings were observed in the livers
of the group treated with HL-25, which were fairly similar to
normal livers. These results indicate that HL-25 could have the
anti-metastatic effects on the liver metastasis mouse models
in vivo.
2.5. Induction of apoptosis by HL-25
We examined the mechanism of the therapeutic effects of HL-
25 on the liver metastasis of HCT116 cells in vivo using the
TUNEL method. HL-25 was administered into the caudal vein of
mice once each for 14 days after the HCT116 cells were inoculated
to mice. Liver was removed from anaesthetized mice immediately
after the treatment with HL-25. As shown in Fig. 5, many apoptotic
cells were observed in the tumor cells in the liver tissue of the
group treated with HL-25. On the other hand, no apoptotic cells
were observed in the normal and control groups. With regard toFig. 4. HE staining of liver tissue of mouse models of colorectal cancer liver metastases
treated with HL-25. Scale bar, 100 mm.colon cancer cell lines, it has been reported that HL induced
apoptosis in human colon adenocarcinoma in vitro [23]. Further-
more, HL have distinguished between normal colon (CCD33Co)
cells and colon carcinoma (WiDr) cells, then fused and accumu-
lated into the plasma membranes of tumor cells, leading to
apoptosis in vitro [23]. We have reported that HL fused and accu-
mulated into tumor cell membranes, and the apoptosis signal ﬁrst
passed through mitochondria, caspase-9, and caspase-3, second
through Fas, caspase-8, caspase-3 and then reached the nucleus
[15]. Same apoptotic signal-transduction could be possible in this
study. These results suggest that HL-25 have remarkable inhibitory
effects on the mouse models of CRC liver metastases along with
apoptosis in vivo.
2.6. Selective accumulation of HL-25 into tumors
We examined the accumulation of HL-25, including NBDPC as
a ﬂuorescence probe into tumor cells, in the liver of mouse models
of CRC liver metastases using a confocal laser scanning microscope.
The results are shown in Fig. 6A. A decrease of green ﬂuorescence
within 3 h in the liver of normal healthy SCID mice (Control)
treated with HL-25 including NBDPC was obtained. It has been
reported that HL composed of DMPC and polyoxyethylene(23)
dodecyl ether were metabolized in the liver after the intravenous
administration to normal BALB/c mice [28]. On the other hand,
accumulation of HL-25 including NBDPC into tumor cells in the
liver were observed for 24 h. Next, we carried out immunostaining
using carcinoembryonic antigen (CEA) as a histochemical marker
of metastatic colon carcinoma to establish the therapeutic effects
of HL-25. The results are shown in Fig. 6B. CEA positive cells in all
liver tissue of hepatic metastatic mouse models were conﬁrmed
after 7days of the intrasplenic inoculation of HCT116 cells. It is
noteworthy that remarkably high selective accumulation of HL-25
in the CEA positive area was observed as compared with control
and DMPC. Signiﬁcantly, we have reported that a good correlation
between the membrane ﬂuidity of HL and their growth-inhibitions
for colorectal cancer cells in vitro [23]. HL having larger membrane
ﬂuidity showed higher inhibitory effects on the growth of colo-
rectal cancer cells. Furthermore, we also reported that HL distin-
guished between normal colon CCD33Co cells and tumor colon
WiDr cells, then fused and accumulated into the plasma
membranes of tumor cells, leading to apoptosis [23]. In addition,
we have already reported that HL have no side-effects in vivo in the
safety tests intravenously administered via a vein once a day for 14
days (mice) [18] and six months (rats) [21,22]. These results
Fig. 6. (A) Selective accumulation of HL-25 including NBDPC into liver on mouse models of CRC liver metastases after 7days of the intrasplenic inoculation of HCT116 cells. Control:
Liver section of normal healthy mice after the intravenous administration with HL-25. DMPC: Liver section of mouse models of CRC liver metastases treated with DMPC liposomes.
HL-25: Liver section of mouse models of CRC liver metastases treated with HL-25. (B) CEA immunostaining of liver tissue of hepatic metastatic mouse models treated with HL-25 for
6 h after 7days of the intrasplenic inoculation of HCT116 cells. Control: Liver section of mouse models of CRC liver metastases without treatment. DMPC: Liver section of mouse
models of CRC liver metastases treated with DMPC liposomes. HL-25: Liver section of mouse models of CRC liver metastases treated with HL-25.
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the liver of mouse models of CRC liver metastases and inhibit the
growth of HCT116 cells.
3. Conclusion
We clearly demonstrated that the therapeutic effects of HL-25
along with apoptosis were obtained for xenograft mouse models
having human CRC liver metastases. The noteworthy aspects in
this study are as follows: (a) Prolonged survival was obtained in
mouse models of CRC liver metastases after the treatment with
HL-25. (b) Remarkably high therapeutic effects of HL were ob-
tained in mouse models of CRC liver metastases on the basis of an
autopsy, relative liver weight, and hematoxylineeosin staining.
(c) Induction of apoptosis was observed in mouse models of CRC
liver metastases after the treatment with HL-25 on the basis of
the TUNEL method. (d) Accumulation of ﬂuorescent labeled HL-
25 was observed in the liver tissue of xenograft mouse models
of CRC liver metastases for 24 h after the intravenous injection.
The results in this study should be advantageous in the chemo-
therapy for patients with CRC liver metastases in clinical
applications.4. Experimental section
4.1. Preparation of hybrid liposomes
Hybrid liposomes (HL) were prepared by sonication of
a mixture containing 95 mol% L-a-dimyristoylphosphatidylcho-
line (DMPC, NOF, Japan) and 5 mol% polyoxyethylene(25)
dodecy ether (C12(EO)23, Nikko Chemicals, Tokyo, Japan) in
5% glucose solution using bath type sonicater (VS-N300,
VELVO-CLEAR, Japan) at 45 C with 300 W as shown in Fig. 1A,
and ﬁltered with a 0.20 mm cellulose acetate ﬁlter (Advantec,
Japan).
4.2. Dynamic light scattering measurements
The diameter of HL was measured with a light scattering
spectrometer (ELS-8000, Otsuka Electronics, Japan) using a Hee
Ne laser (633 nm) at a 90 scattering angle. The diameter
(dhy) was calculated using the StokeseEinstein formula (Equa-
tion (1)), where k is the Boltzmann constant, T is the
absolute temperature, h is the viscosity and D is the diffusion
coefﬁcient:
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Human colon carcinoma (HCT116) cell lines were purchased
from the American Type Culture Collection (Manassas, VA). HCT116
cells were maintained in RPMI-1640 medium (Gibco, Gaithersburg,
MD) supplemented with penicillin 100 U/mL, streptomycin 50 mg/
mL, and 10% fetal bovine serum (HyClone Laboratories, Logan, UT).
The cells were cultured in a 5% CO2 humidiﬁed incubator at 37 C.
4.4. Assessment of antitumor effects in vivo
The mice were handled in accordance with the guidelines for
animal experimentation set out in Japanese law. The animal studies
were approved by the Committee on Animal Research of Sojo
University. Female SCID mice (C.B-17/Icr-scid) were obtained from
CLEA (Tokyo, Japan). The mice were randomly grouped on the basis
of body weight by the stratiﬁed randomization method. The
number of mice was ﬁve in each group. The HCT116 cells (5.0  106
cells) were intrasplenically transplanted into the SCIDmice [25]. HL
(Dose: 136mg/kg for DMPC) were intravenously administered once
each day for 14 days after the inoculation of HCT116 cells. The livers
were weighed after anatomizing the mice after 14 days of inocu-
lation of HCT116 cells, and held an autopsy, and ﬁxed in 10%
formalin solution. The livers were embedded in parafﬁn and
sectioned at 5 mm of thickness. The liver sections were stained with
hematoxylin and eosin (HE) and observed by optical microscope
(Nikon TS-100, Tokyo, Japan).
4.5. TUNEL method
Detection of apoptotic cells was performed on the basis of the
TUNEL method using an in situ apoptosis detection kit (ApopTag
Plus Peroxidase, Intergen, U.S.A) according to manufacturer’s
directions. HCT116 cells (5.0  106 cells) suspended were intra-
splenically inoculated into SCID mice. HL-25 was administered into
the caudal vein of mice once each for 14 days after the HCT116 cells
were inoculated to mice. Liver was removed from anaesthetized
mice after the treatment with HL-25 and ﬁxed in 10% formalin
solution. Parafﬁn-embedded sections weremade, and the detection
of apoptosis of a tumor cell in liver was performed on the basis of
the TUNEL assay according to the conventional method.
4.6. Assessment of survival rate in vivo
For assessment of survival rate, female SCID mice (C.B-17/Icr-
scid) were obtained from CLEA (Tokyo, Japan). The mice were
randomly grouped on the basis of body weight by the stratiﬁed
randomizationmethod. The number of micewas ﬁve in each group.
The HCT116 cells (5.0  106 cells) were intrasplenically trans-
planted into the mice. HL (Dose: 136 mg/kg for DMPC) were
intravenously administered once each day for 14 days after the
inoculation of HCT116 cells. After dosing period, survival of mice
were followed. The median lifespan was calculated using following
the equation, median lifespan ¼ (median survival days after the
treatment)/(median survival days of control group)  100.
4.7. Pharmacokinetics and immunostaining with CEA
The fusion and accumulation into the membrane of OS-RC-2
cells of HL including a ﬂuorescence probe (1-palmitoyl-2-[12-[(7-
nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sn-glycero-3-
phosphocholine) (NBDPC; Avanti Polar Lipids, Alabama, U.S.A.) wasperformed. Female SCID mice (C.B-17/Icr-scid) were obtained from
CLEA (Tokyo, Japan). The mice were randomly grouped on the basis
of body weight by the stratiﬁed randomization method. The
number of mice was three in each group. The HCT116 cells
(5.0  106 cells) were intrasplenically transplanted into the mice.
HL including NBDPC were intravenously administered for mice
after 7days of the inoculation of HCT116 cells. The livers were
resected from the mouse models, and embedded directly in
optimum cutting temperature (OCT) compound (Sakura Finetek,
Tokyo, Japan) at room temperature. The OCT-embedded livers were
rapidly frozen in hexane/dry ice at 20 C, and then the frozen
tissue blocks were cut into 5 mm sections using a freezing micro-
tome (Leica CM1850, Wetzlar, Germany). Furthermore, the sections
were incubated with anti human carcinoembryonic antigen (CEA)
rabbit polyclonal antibody (NBP1-4003, Novus, U.S.A.) at 4 C for
1 h and with Alexa Fluor 594 donkey anti-rabbit IgG(H þ L)
(Molecular Probes, U.S.A.) in humidiﬁed box at 4 C for 1 h. The
cryosections of the liver tissue were observed by confocal micro-
scope (Leica TCS-SP, Heidelberg, Germany) using a 488 nm Ar laser
(detection, NBD:515e555 nm, Alexa Fluor 594:560e620 nm).4.8. Statistical analysis
Results are presented as mean  S.D. Data were statistically
analyzed using Student’s t-test. A p value of less than 0.05 was
considered to represent a statistically signiﬁcant difference.Acknowledgments
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